A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease

Inclusion Criteria:

- Participant must have completed Study M13-740 through Week 52.

- If female, participant must be postmenopausal, surgically sterile or using a birth
control method.

Exclusion Criteria:

- For any reason participant is considered by the investigator to be an unsuitable
candidate

- Female participant with a positive pregnancy test at Baseline or who is considering
becoming pregnant during the study.

- Participant is not in compliance with prior and concomitant medication requirements
and procedures throughout Study M13-740.